Australia Antifungal Drugs Market Size & Outlook, 2026-2033

The antifungal drugs market in Australia is expected to reach a projected revenue of US$ 345.1 million by 2033. A compound annual growth rate of 5.2% is expected of Australia antifungal drugs market from 2026 to 2033.
Revenue, 2025 (US$M)
$230.9
Forecast, 2033 (US$M)
$345.1
CAGR, 2026 - 2033
5.2%
Report Coverage
Australia

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

Australia antifungal drugs market, 2021-2033 (US$M)

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

Australia antifungal drugs market highlights

  • The Australia antifungal drugs market generated a revenue of USD 230.9 million in 2025 and is expected to reach USD 345.1 million by 2033.
  • The Australia market is expected to grow at a CAGR of 5.2% from 2026 to 2033.
  • In terms of segment, azoles was the largest revenue generating drug class in 2025.
  • Echinocandins is the most lucrative drug class segment registering the fastest growth during the forecast period.


Antifungal drugs market data book summary

Market revenue in 2025USD 230.9 million
Market revenue in 2033USD 345.1 million
Growth rate5.2% (CAGR from 2026 to 2033)
Largest segmentAzoles
Fastest growing segmentEchinocandins
Historical data2021 - 2024
Base year2025
Forecast period2026 - 2033
Quantitative unitsRevenue in USD million
Market segmentationAzoles, Echinocandins, Polyenes, Allylamines
Key market players worldwideNovartis AG ADR, Pfizer Inc, Bayer AG, Sanofi SA, Merck KGaA, Merck & Co Inc, GlaxoSmithKline, Abbott Laboratories, Enzon Pharmaceuticals Inc, Astellas Pharma Inc, Glenmark Pharmaceuticals


Other key industry trends

  • In terms of revenue, Australia accounted for 1.4% of the global antifungal drugs market in 2025.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
  • In Asia Pacific, Japan antifungal drugs market is projected to lead the regional market in terms of revenue in 2033.
  • China is the fastest growing regional market in Asia Pacific and is projected to reach USD 1,710.7 million by 2033.

Azoles was the largest segment with a revenue share of 50.63% in 2025. Horizon Databook has segmented the Australia antifungal drugs market based on azoles, echinocandins, polyenes, allylamines covering the revenue growth of each sub-segment from 2021 to 2033.


Players are entering the market to capitalize on opportunities in the lucrative market. For instance, Cresemba (isavuconazole) was launched in Australia by Pfizer, Inc., which holds sales license for the product in Asia Pacific. 

This drug is from azole class and is used for mucormycosis and invasive aspergillosis treatment. This drug is expected to provide a new treatment option to patients. Furthermore, the Pharmaceutical Benefits Scheme covers antifungal drugs, which improves access to these drugs. 

Moreover, key players, such as Bayer, are organizing campaigns across the nation to improve awareness among the young population. This is expected to improve fungal infection diagnosis rate and increase treatment rate, thereby propelling antifungal drugs market growth.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Antifungal Drugs Market Companies

Name Profile # Employees HQ Website
Glenmark Pharmaceuticals View profile 10001+ Andheri, Maharashtra, India, Asia http://www.glenmarkpharma.com
GlaxoSmithKline View profile 10001+ London, England, United Kingdom, Europe http://www.gsk.com
Astellas Pharma Inc View profile 14484 2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, Japan, 103-8411 http://www.astellas.com
Enzon Pharmaceuticals Inc View profile 1 20 Commerce Drive, Suite 135, Cranford, NJ, United States, 07016 http://www.enzon.com
Bayer AG View profile 99723 Kaiser-Wilhelm-Allee 1, Leverkusen, NW, Germany, 51368 https://www.bayer.com
Merck & Co Inc View profile 72000 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 https://www.merck.com
Sanofi SA View profile 87994 46, avenue de la Grande Armée, Paris, France, 75017 https://www.sanofi.com
Pfizer Inc View profile 88000 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 https://www.pfizer.com
Abbott Laboratories View profile 114000 100 Abbott Park Road, Abbott Park, IL, United States, 60064-6400 https://www.abbottinvestor.com
Merck KGaA View profile 62345 Frankfurter Strasse 250, Darmstadt, HE, Germany, 64293 https://www.emdgroup.com
Novartis AG ADR View profile 76057 Lichtstrasse 35, Basel, Switzerland, 4056 https://www.novartis.com

Australia antifungal drugs market size, by drug class, 2021-2033 (US$M)

Australia Antifungal Drugs Market Outlook Share, 2025 & 2033 (US$M)

Australia antifungal drugs market size, by drug class, 2021-2033 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more
Chat with us
Research Assistance
Online